Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26+ leukemia stem cells
Introduction: In chronic myeloid leukemia (CML), about half of the patients achieving a deep and stable molecular response with tyrosine kinase inhibitors (TKIs) may discontinue TKI treatment without disease recurrence. As such, treatment-free remission (TFR) has become an ambitious goal of treatmen...
Saved in:
Main Authors: | Paola Pacelli (Author), Adele Santoni (Author), Anna Sicuranza (Author), Elisabetta Abruzzese (Author), Valentina Giai (Author), Monica Crugnola (Author), Mario Annunziata (Author), Sara Galimberti (Author), Alessandra Iurlo (Author), Luigiana Luciano (Author), Federica Sorà (Author), Carmen Fava (Author), Elena Bestoso (Author), Cristina Marzano (Author), Alessandra Cartocci (Author), Marzia Defina (Author), Vincenzo Sammartano (Author), Emanuele Cencini (Author), Donatella Raspadori (Author), Monica Bocchia (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The TKI Era in Chronic Leukemias
by: Danilo De Novellis, et al.
Published: (2021) -
Anti CD38 monoclonal antibodies for multiple myeloma treatment
by: Alessandro Gozzetti, et al.
Published: (2022) -
A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia
by: Sara Galimberti, et al.
Published: (2024) -
Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy
by: Bocchia M, et al.
Published: (2022) -
The Role of Monoclonal Antibodies in the Management of Leukemia
by: Mohamad Cherry, et al.
Published: (2010)